Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. It develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER).
Revenue growth (FY, 2019 - FY, 2020), %
Net income (FY, 2020)
EBIT (FY, 2020)
Market capitalization (22-Jul-2021)
Closing stock price (22-Jul-2021)
Immatics has 1.19k Twitter Followers. The number of followers has increased 0.4% month over month and increased 1.6% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
Who are Immatics key executives?
Immatics's key executives are Peter Chambré, Harpreet Singh and Arnd Christ.
How many employees does Immatics have?
Immatics has 230 employees.
What is Immatics revenue?
Latest Immatics annual revenue is €31.3 m.
What is Immatics revenue per employee?
Latest Immatics revenue per employee is €135.9 k.
Who are Immatics competitors?
Competitors of Immatics include Eureka Therapeutics, Tessa Therapeutics and Juno Therapeutics.
Where is Immatics headquarters?
Immatics headquarters is located at Paul-Ehrlich-Str. 15, Tübingen.
Where are Immatics offices?
Immatics has offices in Tübingen, München and Houston.
How many offices does Immatics have?
Immatics has 3 offices.
Receive alerts for 300+ data fields across thousands of companies